Difference between revisions of "Relugolix (Orgovyx)"
(patient drug info) |
m |
||
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*12/18/2020: Approved for adult patients with advanced [[prostate cancer]]. ''(Based on HERO)'' | *12/18/2020: Approved for adult patients with advanced [[prostate cancer]]. ''(Based on HERO)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *4/29/2022: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' TAK-385 | *'''Code name:''' TAK-385 | ||
| Line 29: | Line 30: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Revision as of 00:44, 1 January 2023
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 12/18/2020: Approved for adult patients with advanced prostate cancer. (Based on HERO)
History of changes in EMA indication
- 4/29/2022: Initial authorization
Also known as
- Code name: TAK-385
- Brand names: Orgovyx, Relumina